How to Scale DNA Production Effectively to Meet the Needs of Genetic Medicines
DNA is the blueprint of life, carrying the molecular instructions that tell every cell how to function. As we learn more about this code, our ability to rewrite it – and correct problems when they arise – continues to grow.
Genetic medicines use DNA to reprogramme cells, repair or replace lost functions, and train the immune system to fight disease with remarkable precision. From cancer and neurodegenerative disorders to infectious diseases, these DNA-based therapies are opening up exciting new possibilities in healthcare.
However, progress in this field relies on a reliable, scalable supply of high-quality DNA, and traditional manufacturing methods simply can’t keep up. In this blog, we explore the growing demand for genetic therapies, why reliance on plasmid DNA creates bottlenecks, and how our dbDNA™ technology provides a faster, more cost-effective, and scalable solution.
The Rising Demand for DNA in Genetic Medicines
The demand for genetic medicines is significantly growing due to advancements in genetic technologies, the growing burden of genetic disorders, and the push for more personalised and precise healthcare.
The global cell and gene therapy market is rapidly expanding, estimated at USD 25.03 billion in 2025 and projected to reach USD 117.46 billion by 2034. These medicines offer powerful new ways to treat a range of conditions, from rare inherited disorders to complex neurodegenerative diseases. By correcting or replacing faulty genes, gene therapies hold the potential not only to treat but even to cure diseases once thought untreatable.
Although mRNA vaccines, had been in development for many years, they came to global attention during the COVID-19 pandemic, when they were quickly developed and deployed at scale. Their success demonstrated the power of using genetic instructions to train the immune system. Since then, research has expanded rapidly beyond COVID-19 into areas such as cancer, infectious diseases, genetic disorders and cardiovascular diseases.
Currently, mRNA is being investigated for personalised cancer vaccines, a form of cancer immunotherapy. Unlike chemotherapy and radiotherapy, which affect both healthy and cancerous cells, these vaccines are designed to target only the tumour. By sequencing a patient’s tumour to identify unique mutations, scientists can create a bespoke mRNA vaccine that trains the immune system to exclusively recognise and eliminate cancer cells while sparing healthy tissue. Although still in early clinical trials, personalised cancer vaccines could offer highly precise, individualised treatments, providing better outcomes and fewer side effects.
Cell therapies are also advancing the field of cancer immunotherapy. CAR-T cell treatments have shown highly promising results in blood cancers, and researchers are now working to improve their ability to treat solid tumours. If successful, these therapies could provide patients with effective, targeted options where few currently exist.
But as demand for these types of genetic medicines grows, so too does the need for plasmid DNA, the critical starting material used to manufacture them. However, reliance on plasmid DNA has become a major bottleneck, limiting the speed and scale needed to keep pace with modern genetic medicine.
Why Plasmid DNA is Holding Back Genetic Medicine
Currently, most plasmid DNA is made by inserting the desired genetic sequence into a plasmid, growing it in bacteria, and then extracting and purifying the DNA. This process is slow, costly, and can take up to a year for GMP-grade material, due to complex fermentation, purification, and quality control steps. It also depends on expensive specialist facilities, equipment, and highly trained staff, all of which restrict the scalability of large-scale production.
Additionally, because plasmid DNA is produced in bacteria, it often carries unwanted bacterial sequences such as antibiotic resistance genes, which can raise safety concerns and delay development. Plasmid DNA also faces fidelity issues, as certain DNA elements are structurally unstable in E. coli, leading to deletions or rearrangements that compromise sequence integrity and reduce consistency.
Meeting the demand for genetic medicines with dbDNA™ technology
We know that to realise the potential of genetic medicines, we must come up with a better way to make DNA. That’s why we developed our dbDNA technology, an advanced cell-free DNA platform that produces synthetic dbDNA through an in vitro enzymatic process rather than using bacterial cells. This platform supports a range of applications, including viral vectors, non-viral, mRNA, gene editing and vaccine applications, offering safer, scalable and more economical alternatives to traditional plasmid-based methods.
Key advantages of dbDNA technology for your workflows include:
- Rapid production – Multi-gram quantities manufactured in weeks compared with the many months for plasmid DNA, bringing therapies to market quicker.
- High purity – A fully cell-free process eliminates bacterial contaminants such as antibiotic resistance genes, improving safety and simplifying downstream workflows.
- Scalability – Easily scaled from research to clinical and commercial supply, without the need for specialist equipment and extensive fermentation processes.
- High fidelity – Enzymatic amplification preserves complex or unstable DNA regions that are difficult to maintain in plasmids, ensuring consistent sequence integrity.
- Cost efficiency – High-expression performance reduces DNA input requirements, and the streamlined process lowers overall development and manufacturing costs.
Summary
Genetic medicines hold enormous promise for the future of healthcare, with the potential to deliver long-term, disease-modifying treatments across many conditions. Most excitingly, they open the door to more precise and personalised approaches that can drastically improve outcomes for patients.
Realising this potential depends on fast, scalable DNA production. Technologies like dbDNA make this possible. By producing DNA rapidly, cleanly, and at scale, dbDNA technology removes the bottlenecks of plasmid production and provides the reliable foundation needed to accelerate life-changing therapies for patients.
To learn more about how our dbDNA can accelerate your genetic medicine projects, get in touch or explore our technology further.
